Technical Analysis for ATRA - Atara Biotherapeutics, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 0.69 | -1.40% | -0.01 |
ATRA closed down 1.4 percent on Friday, April 26, 2024, on 30 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
Earnings due: May 6
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Bollinger Band Squeeze | Range Contraction | 0.00% | |
NR7 | Range Contraction | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Inside Day | Range Contraction | 0.00% | |
Down 3 Days in a Row | Weakness | 0.00% | |
20 DMA Resistance | Bearish | -1.40% | |
50 DMA Resistance | Bearish | -1.40% | |
Bollinger Band Squeeze | Range Contraction | -1.40% | |
50 DMA Resistance | Bearish | -3.46% | |
Fell Below 20 DMA | Bearish | -3.46% |
Alert | Time |
---|---|
60 Minute Opening Range Breakout | about 17 hours ago |
Up 1% | about 17 hours ago |
Possible NR7 | about 17 hours ago |
Possible Inside Day | about 17 hours ago |
10 DMA Support | about 20 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/06/2024
Atara Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of muscle wasting conditions and oncology. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. The company is also developing STM 434, a targeted therapy for ovarian cancer and other solid tumors; and a pipeline of product candidates that are in preclinical development. Atara Biotherapeutics, Inc. was founded in 2012 and is headquartered in Brisbane, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Solid Tumors Drugs Clinical Development Ovarian Cancer Targeted Therapy End Stage Renal Disease Renal Disease Stage Renal Disease
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Solid Tumors Drugs Clinical Development Ovarian Cancer Targeted Therapy End Stage Renal Disease Renal Disease Stage Renal Disease
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 3.015 |
52 Week Low | 0.1986 |
Average Volume | 1,731,572 |
200-Day Moving Average | 1.08 |
50-Day Moving Average | 0.72 |
20-Day Moving Average | 0.72 |
10-Day Moving Average | 0.69 |
Average True Range | 0.06 |
RSI (14) | 46.52 |
ADX | 16.8 |
+DI | 17.06 |
-DI | 18.34 |
Chandelier Exit (Long, 3 ATRs) | 0.65 |
Chandelier Exit (Short, 3 ATRs) | 0.82 |
Upper Bollinger Bands | 0.78 |
Lower Bollinger Band | 0.66 |
Percent B (%b) | 0.28 |
BandWidth | 16.68 |
MACD Line | 0.00 |
MACD Signal Line | 0.00 |
MACD Histogram | -0.0008 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.73 | ||||
Resistance 3 (R3) | 0.74 | 0.72 | 0.73 | ||
Resistance 2 (R2) | 0.72 | 0.71 | 0.72 | 0.72 | |
Resistance 1 (R1) | 0.71 | 0.70 | 0.70 | 0.70 | 0.72 |
Pivot Point | 0.69 | 0.69 | 0.69 | 0.69 | 0.69 |
Support 1 (S1) | 0.68 | 0.68 | 0.68 | 0.68 | 0.66 |
Support 2 (S2) | 0.66 | 0.67 | 0.66 | 0.66 | |
Support 3 (S3) | 0.65 | 0.66 | 0.65 | ||
Support 4 (S4) | 0.65 |